Objective To observe the clinical efficacy of diltiazem in patients with coronary disease following percutaneous coronary intervention(PCI).Methods From Jan 2014 to Jan 2016,116 cases of coronary disease were selected as the research subjects,they were randomly divided into the observation group(62cases)and the control group(54 cases).The control group was given conventional therapy,while the observation group was given diltiazem therapy on the basis of control group.The levels of BP,HR,NT -proBNP,CRP and angina frequency in the two groups were compared before and 24h,48h after PCI.The incidence of major adverse cardiovascular events(MACEs) was assessed at the sixth month after PCI.Results After surgery,the CRP levels of the observation group and control group were (40.1 ±7.4)mg/L and (41.7 ±8.8)mg/L,the NT -proBNP levels of the two groups were (501.8 ± 56.5)ng/L and (445.7 ±50.6)ng/L,which were significantly higher than preoperation(t =5.684,P <0.05).The blood pressure,heart rate,CRP,NT -proBNP of the observation group since 24 hours after PCI were (73.1 ± 6.2)mmHg,(121.7 ±15.8)mmHg,(68.1 ±7.9)times/min,(24.8 ±3.7)mg/L,(201.7 ±20.6)ng/L,which were significantly lower than those of control group [(85.6 ±9.3 )mmHg,(134.3 ±17.4)mmHg,(77.5 ± 9.2)times/min,(36.5 ±7.9)mg/L,(481.5 ±48.2)ng/L].The effect was kept over 48 hours(F =7.281,8.097, 6.945,7.682,6.517,all P <0.05).Angina pectoris after treatment in the observation group and control group were (1.5 ±0.9)times/month,(2.9 ±0.7)times/month,which were significantly lower than before treatment(t =7.584,P <0.05).The incidence rate of total MACE in the observation group was 4.84%,which was significantly lower than that in the control group(χ2 =6.942,P <0.05).Conclusion Diltiazem after PCI can decrease the adverse reaction, and help to improve the prognosis of patients.

Objective:To investigate the survival rates of patients with liver cancer in Shanghai from 2002 to 2013. Methods:Data on new cases and deaths of liver cancer patients withfollow-up information from 2002 to 2013 were obtained from the Population-Based Cancer Registry and Vital Statistics System of the Shanghai Municipal Center for Disease Control and Prevention.Incidence and survival rates were stratified by year of diagnosis,gender,district,age-group and stage at diagnosis for analysis.Statistical indicators,such as case numbers,proportions,median age and mean age were calculated.The 1-to 5-year observed survival rates were calculated based on the life table method.The probabilities of surviving from 0 to 99 years old were estimated with the Elandt-Johnson model,and then cumulative expected survival rates were calculated using the Ederer Ⅱ method.Finally,the 1-to 5-year relative survival rates were calculated. Results:A total of 49 455 new cases of liver cancer were diagnosed from 2002 to 2013 in Shanghai,including 35 115 males and 14 340 females.The ratio of males to females was 2.45:1.The proportions of stage Ⅰ,stage Ⅳ and stage unknown were 3.32％,13.93％and 69.13％,respectively.The median survival time of patients with liver cancer diagnosed from 2002 to 2013 was 0.77 years,the 5-year observed survival rate was 13.23％,and the 5-year relative survival rate was 14.47％.According to the 5-year observed survival rate and 5-year relative survival rate of the cases,both survival indicators were higher in urban areas than in suburban areas,higher in males than in females,higher in cases under 45 years of age than in those over 75 years of age,higher in cases diagnosed from 2011 to 2013 than those diagnosed from 2002 to 2004.Additionally,the survival rate of cases decreased with increasing stage at diagnosis. Conclusion:With the continuous improvement of the diagnosis and treatment of liver cancer in Shanghai,the survival rate of patients with liver cancer has shown a significant upward trend over time.However,compared with various malignant tumors such as gastric cancer and breast cancer,the improvement effect of liver cancer survival rate is still not significant.Additionally,a high proportion of cases with unknown clinical stage at the time of diagnosis and a low survival rate of stage Ⅳ cases were observed.This study provides a basis for the prevention and research of liver cancer.

【Objective】 To compare the clinical efficacy of transperineal prostate laser ablation (TPLA) and transurethral resection of the prostate (TURP) in the treatment of benign prostatic hyperplasia (BPH). 【Methods】 A total of 60 BPH patients diagnosed during Oct. 2021 and Oct. 2022 at Tangdu Hospital were selected as the research subjects and randomly divided into the TPLA group (n=30) and TURP group (n=30). The intraoperative bleeding volume, operation time, catheter indwelling time, length of hospital stay, postoperative sexual dysfunction, and surgical related complications were compared between the two groups. The international prostate symptom score (IPSS), international index of erectile function-5 (IIEF-5), maximum urinary flow rate (Qmax), quality of life score (QoL), postvoid residual (PVR) and prostate volume (PV) were compared between the two groups before surgery and 1, 3, and 12 months after surgery. 【Results】 The TPLA group had significantly less intraoperative bleeding volume, shorter operation time and length of hospital stay compared to the TURP group, but longer catheter indwelling time (P<0.05). Both groups showed significant improvement in IPSS and Qmax 1, 3, and 12 months postoperatively compared to preoperative (P<0.05), the IPSS of the TPLA group was significantly higher than that of the TURP group 1 and 3 months after surgery (P<0.05); the Qmax of TPLA group 1, 3, and 12 months after surgery was lower than that of the TURP group (P<0.05). The IIEF-5 score was significantly better in the TPLA group than in the TURP group after surgery (P<0.05). The postoperative QoL, PV, and PVR levels in both groups improved after surgery (P<0.05), the QoL of the TPLA group was lower than that of the TURP group 1 and 12 months after surgery (P<0.05), the PV and PVR of the TPLA group were higher than those of the TURP group 1, 3, and 12 months after surgery (P<0.05). The incidence of surgery-related complications (3.33% vs. 26.67%) and postoperative sexual dysfunction (3.33% vs. 36.67%) in the TPLA group were lower than those in the TURP group (P<0.05). 【Conclusion】 TPLA shows significant efficacy in treating BPH with minimal impact on the sexual function. It provides a new approach for BPH patients and can serve as an effective complementary method in clinical practice.